Comparative Pharmacology
Head-to-head clinical analysis: CEPHAPIRIN SODIUM versus KEFLIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CEPHAPIRIN SODIUM versus KEFLIN.
CEPHAPIRIN SODIUM vs KEFLIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Cephapirin sodium is a first-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), primarily PBP1 and PBP3, thereby inhibiting transpeptidation and disrupting peptidoglycan cross-linking, leading to cell lysis mediated by autolytic enzymes.
Cephalosporin antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin activation, leading to cell lysis.
500 mg to 1 g IM or IV every 6 hours.
1-2 g IV/IM every 4-6 hours; maximum 12 g/day.
None Documented
None Documented
0.5-1.0 hours; prolonged to 2-5 hours in renal impairment, requiring dose adjustment.
Terminal elimination half-life: 0.5-1 hour (normal renal function); prolonged to 2-3 hours in anuria. Clinically, dosing every 6 hours is recommended.
Renal: 80-90% unchanged via glomerular filtration and tubular secretion; biliary/fecal: <5%.
Renal: 70-80% unchanged via glomerular filtration and tubular secretion; biliary: minimal (<5%); fecal: <1%.
Category C
Category C
Cephalosporin Antibiotic
Cephalosporin Antibiotic